Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma

Run-Bin Liang(Sun Yat-sen University), Ming Shi(Yanshan University), Anna Kan(Sun Yat-sen University), Yaojun Zhang(Sun Yat-sen University), ZhiCheng Lai(Sun Yat-sen University), YeXing Huang(Sun Yat-sen University), Dongsheng Wen(Technical University of Munich), QiJiong Li(Sun Yat-sen University), Yujie Xu(Henan University), Wei Wei(Zhujiang Hospital), Yang Zhao, Xiaoyun Bu(Xiamen Blood Center), Minshan Chen(Sun Yat-sen University), Minke He(Sun Yat-sen University), Rong Guo(Sun Yat-sen University)
Frontiers in Oncology
May 12, 2021
10.3389/fonc.2021.619461
Cited by 20

Related Papers

Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion
|JAMA Oncology|2019|559
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
|The Lancet|2023|514
Circulating Mitochondrial DNA in Patients in the ICU as a Marker of Mortality: Derivation and Validation
|PLoS Medicine|2013|449
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217